327 related articles for article (PubMed ID: 29656754)
1. Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations.
Sneddon S; Dick I; Lee YCG; Musk AWB; Patch AM; Pearson JV; Waddell N; Allcock RJN; Holt RA; Robinson BWS; Creaney J
Lung Cancer; 2018 May; 119():64-70. PubMed ID: 29656754
[TBL] [Abstract][Full Text] [Related]
2. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma.
Guo G; Chmielecki J; Goparaju C; Heguy A; Dolgalev I; Carbone M; Seepo S; Meyerson M; Pass HI
Cancer Res; 2015 Jan; 75(2):264-9. PubMed ID: 25488749
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of
Kukuyan AM; Sementino E; Kadariya Y; Menges CW; Cheung M; Tan Y; Cai KQ; Slifker MJ; Peri S; Klein-Szanto AJ; Rauscher FJ; Testa JR
Cancer Res; 2019 Aug; 79(16):4113-4123. PubMed ID: 31151962
[TBL] [Abstract][Full Text] [Related]
4. BAP1 mutation is a frequent somatic event in peritoneal malignant mesothelioma.
Alakus H; Yost SE; Woo B; French R; Lin GY; Jepsen K; Frazer KA; Lowy AM; Harismendy O
J Transl Med; 2015 Apr; 13():122. PubMed ID: 25889843
[TBL] [Abstract][Full Text] [Related]
5. Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma.
Kalra N; Zhang J; Thomas A; Xi L; Cheung M; Talarchek J; Burkett S; Tsokos MG; Chen Y; Raffeld M; Miettinen M; Pastan I; Testa JR; Hassan R
BMC Cancer; 2015 May; 15():376. PubMed ID: 25952750
[TBL] [Abstract][Full Text] [Related]
6. BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas.
Leblay N; Leprêtre F; Le Stang N; Gautier-Stein A; Villeneuve L; Isaac S; Maillet D; Galateau-Sallé F; Villenet C; Sebda S; Goracci A; Byrnes G; McKay JD; Figeac M; Glehen O; Gilly FN; Foll M; Fernandez-Cuesta L; Brevet M
J Thorac Oncol; 2017 Apr; 12(4):724-733. PubMed ID: 28034829
[TBL] [Abstract][Full Text] [Related]
7. Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens.
Hwang HC; Sheffield BS; Rodriguez S; Thompson K; Tse CH; Gown AM; Churg A
Am J Surg Pathol; 2016 Jan; 40(1):120-6. PubMed ID: 26448191
[TBL] [Abstract][Full Text] [Related]
8. An asbestos-exposed family with multiple cases of pleural malignant mesothelioma without inheritance of a predisposing BAP1 mutation.
Cheung M; Kadariya Y; Pei J; Talarchek J; Facciolo F; Visca P; Righi L; Cozzi I; Testa JR; Ascoli V
Cancer Genet; 2015 Oct; 208(10):502-7. PubMed ID: 26364129
[TBL] [Abstract][Full Text] [Related]
9. Whole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma.
Sneddon S; Patch AM; Dick IM; Kazakoff S; Pearson JV; Waddell N; Allcock RJN; Holt RA; Robinson BWS; Creaney J
BMC Cancer; 2017 Jun; 17(1):396. PubMed ID: 28577549
[TBL] [Abstract][Full Text] [Related]
10. Driver Gene and Novel Mutations in Asbestos-Exposed Lung Adenocarcinoma and Malignant Mesothelioma Detected by Exome Sequencing.
Mäki-Nevala S; Sarhadi VK; Knuuttila A; Scheinin I; Ellonen P; Lagström S; Rönty M; Kettunen E; Husgafvel-Pursiainen K; Wolff H; Knuutila S
Lung; 2016 Feb; 194(1):125-35. PubMed ID: 26463840
[TBL] [Abstract][Full Text] [Related]
11. CDKN2A copy number and p16 expression in malignant pleural mesothelioma in relation to asbestos exposure.
Kettunen E; Savukoski S; Salmenkivi K; Böhling T; Vanhala E; Kuosma E; Anttila S; Wolff H
BMC Cancer; 2019 May; 19(1):507. PubMed ID: 31138176
[TBL] [Abstract][Full Text] [Related]
12. Genomic Deletion of
Sarun KH; Lee K; Williams M; Wright CM; Clarke CJ; Cheng NC; Takahashi K; Cheng YY
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30301262
[TBL] [Abstract][Full Text] [Related]
13. Molecular characterization of localized pleural mesothelioma.
Hung YP; Dong F; Dubuc AM; Dal Cin P; Bueno R; Chirieac LR
Mod Pathol; 2020 Feb; 33(2):271-280. PubMed ID: 31371807
[TBL] [Abstract][Full Text] [Related]
14. Contribution of BAP1 loss and p16 (CDKN2A) deletion analysis to the definitive diagnosis of mesothelioma in effusion cytology.
Aydogdu G; Özekinci S
Eur Rev Med Pharmacol Sci; 2023 Oct; 27(20):10001-10007. PubMed ID: 37916370
[TBL] [Abstract][Full Text] [Related]
15. Recent insights emerging from malignant mesothelioma genome sequencing.
Carbone M; Gaudino G; Yang H
J Thorac Oncol; 2015 Mar; 10(3):409-11. PubMed ID: 25695218
[No Abstract] [Full Text] [Related]
16. Usefulness of methylthioadenosine phosphorylase and BRCA-associated protein 1 immunohistochemistry in the diagnosis of malignant mesothelioma in effusion cytology specimens.
Berg KB; Churg AM; Cheung S; Dacic S
Cancer Cytopathol; 2020 Feb; 128(2):126-132. PubMed ID: 31821740
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic value of BRCA1-associated protein-1, glucose transporter-1 and desmin expression in the discrimination between reactive mesothelial proliferation and malignant mesothelioma in tissues and effusions.
Önder S; Özogul E; Koksal D; Sarinc Ulasli S; Firat P; Emri S
Cytopathology; 2019 Nov; 30(6):592-600. PubMed ID: 31165505
[TBL] [Abstract][Full Text] [Related]
18. Testing for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology.
Chevrier M; Monaco SE; Jerome JA; Galateau-Salle F; Churg A; Dacic S
Cancer Cytopathol; 2020 Dec; 128(12):939-947. PubMed ID: 32678499
[TBL] [Abstract][Full Text] [Related]
19. BAP1 protein is a progression factor in malignant pleural mesothelioma.
Arzt L; Quehenberger F; Halbwedl I; Mairinger T; Popper HH
Pathol Oncol Res; 2014 Jan; 20(1):145-51. PubMed ID: 23963927
[TBL] [Abstract][Full Text] [Related]
20. Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma.
Brich S; Bozzi F; Perrone F; Tamborini E; Cabras AD; Deraco M; Stacchiotti S; Dagrada GP; Pilotti S
Mod Pathol; 2020 Feb; 33(2):217-227. PubMed ID: 31570769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]